No validated, FDA-recognized predictive neuroimaging or molecular biomarker for psychedelic therapy response is established by end of 2027

Scientists are studying brain scans and biological markers trying to figure out in advance which patients will respond best to psychedelic therapy — the same way a blood test can predict how someone will respond to certain cancer drugs. Despite lots of promising research, nobody will have a test that's actually validated and ready for real clinical use by the end of 2027. This matters because without such a test, doctors can't reliably match patients to treatments.

Mechanistic publications on plasticity and connectivity continue to grow, but translating these into a prospectively validated, clinically deployable biomarker requires large confirmatory datasets that are not yet underway. Reframed from a vague 'outpace' claim into a binary, checkable absence-of-validated-biomarker statement.